PharmaShots | Incisive News in 3 Shots

Subscribe Now

HER2-positive metastatic breast cancer

Henlius Signs an Exclusive License Agreement with Accord for HLX02 (biosimilar- trastuzumab) in the US and Canada

Henlius Signs an Exclusive License Agreement with Accord for HLX02 (biosimilar- trastuzumab) in the US and Canada

October 1, 2020

Henlius Reports First Patient Dosing with HLX11 (biosimilar- pertuzumab) for HER2-Positive Metastatic Breast Cancer and Early Breast Cancer

Henlius Reports First Patient Dosing with HLX11 (biosimilar- pertuzumab) for HER2-Positive Metastatic Breast Cancer and Early Brea...

September 20, 2020

Puma Biotechnology Reports Results of Neratinib (PB272) in P-III NALA Trial for 3L HER2-Positive Metastatic Breast Cancer

Puma Biotechnology Reports Results of Neratinib (PB272) in P-III NALA Trial for 3L HER2-Positive Metastatic Breast Cancer

December 19, 2018

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us